Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Delayed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) represents a missed opportunity for intervention. This study estimates the health benefits of timely diagnosis and treatment with tafamidis. Methods: A disease simulation model was developed to predict health outcomes under scenarios of timely and delayed diagnosis and treatment. Efficacy and quality of life (QoL) profiles were derived from the pivotal tafamidis trial and diagnostic delay durations from the literature. Results: Timely diagnosis and treatment were predicted to extend mean life expectancy by 5.46 and 7.76 years, relative to delayed diagnosis, for wild-type and hereditary ATTR-CM, respectively. Corresponding QALY gains were 4.50 and 6.22. Conclusion: Timely diagnosis and treatment with tafamidis are predicted to significantly improve survival and QoL for ATTR-CM patients.
Supplementary Material
File (suppl_file.doc)
- Download
- 387.00 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. JACC 73(22), 2872–2891 (2019).
•• Expert review of transthyretin amyloid cardiomyopathy (ATTR-CM) and its diagnosis.
2.
Maurer MS, Bokhari S, Damy T et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ. Heart Fail. 12(9), e006075 (2019).
•• Expert consensus recommendations on the diagnosis of ATTR-CM, including the use of the latest noninvasive techniques.
3.
Gillmore JD, Damy T, Fontana M et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39(30), 2799–2806 (2017).
4.
Maurer MS, Hanna M, Grogan M et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). JACC 68(2), 161–172 (2016).
5.
Kroi F, Fischer N, Gezin A, Hashim M, Rozenbaum MH. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Cardiol. Ther. 10, 41–55 (2021).
6.
Witteles RM, Bokhari S, Damy T et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 7(8), 709–716 (2019).
•• Guide to early diagnosis of ATTR-CM in clinical practice, including ‘red flags’ that should increase suspicion.
7.
Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14–333 African–Americans. Amyloid 22(3), 171–174 (2015).
8.
Quarta CC, Buxbaum JN, Shah AM et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. N. Engl. J. Med. 372(1), 21–29 (2014).
9.
Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J. Card. Fail. 22(12), 996–1003 (2016).
10.
Alpert CM, Smith MA, Hummel SL, Hummel EK. Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail. Rev. 22(1), 25–39 (2017).
11.
Rapezzi C, Lorenzini M, Longhi S et al. Cardiac amyloidosis: the great pretender. Heart Fail. Rev. 20(2), 117–124 (2015).
12.
Lane T, Fontana M, Martinez-Naharro A et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1), 16–26 (2019).
• Natural history and outcomes of ATTR-CM in a large national cohort.
13.
Rozenbaum MH, Large Samuel, Bhambri Rahul et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol. Ther. 10, 141–159 (2021).
•• Review of the literature on diagnostic delay in ATTR-CM; the findings form the basis of the delay durations modeled in the current study.
14.
Falk RH. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur. Heart J. 40(12), 1009–1012 (2019).
15.
Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24), 2404–2412 (2016).
16.
Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am. J. Med. 128(12), 1275–1280 (2015).
17.
Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol. Ther. 9(2), 317–333 (2020).
18.
ASNC Practice Points: 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis (2018). www.asnc.org/content.asp?contentid=290
19.
Dorbala S, Ando Y, Bokhari S et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-Diagnostic criteria and appropriate utilization. J. Nucl. Cardiol. 27(2), 659–673 (2020).
20.
Nativi-Nicolau J, Siu A, Dispenzieri A et al. Temporal trends of wild-type Attr amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. J. Card. Fail. 26(10), S82 (2020).
21.
Lousada I, Maurer M, Warner M, Guthrie S, Hsu K, Grogan M. Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers. Presented at: XVIth International Symposium on Amyloidosis; 2018 March 26–29 Kumamoto, Japan (2018).
22.
European Medicines Agency. Assessment report: vyndaqel (2019). www.ema.europa.eu/en/documents/variation-report/vyndaqel-h-c-2294-x-0049-g-epar-assessment-report_en.pdf
23.
US Food and Drug Administration. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis (2019). www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated#:~:text=On%20May%203%2C%20the%20U.S.,approved%20treatments%20for%20ATTR%2DCM
24.
Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379(11), 1007–1016 (2018).
25.
Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid 25(3), 174–179 (2018).
26.
Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis – a clinical challenge. Int. J. Cardiol. 304, 138–143 (2020).
27.
TA267: ivabradine for treating chronic heart failure. National Institute for Health and Care Excellence (2012). www.nice.org.uk/Guidance/TA267
28.
TA388: sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. National Institute for Health and Care Excellence (2016). www.nice.org.uk/guidance/ta388
29.
Classes of Heart Failure (2017). American Heart Association. www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
30.
Chen J, Normand S-LT, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 306(15), 1669–1678 (2011).
31.
Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis: a community perspective. JACC 54(18), 1695–1702 (2009).
32.
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18(8), 891–975 (2016).
33.
Pfizer. ATTR-ACT, data on file (2019).
34.
Pfizer. ATTR-ACT extension study (Preliminary August 2019 database lock), data on file (2019).
35.
Arias E, Xu J. United States life tables: 2017. Centers for Disease Control and Prevention (2019).
36.
Shaw JW, Johnson JA, Coons SJJMC. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med. Care 43(3), 203–220 (2005).
37.
Damy T, Garcia-Pavia P, Hanna M et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur. J. Heart Fail. 23(2), 277–285 (2020).
38.
Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 24(1), 30–36 (2017).
39.
Pilgaard T, Pedersen MH, Poulsen SH. Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark. J. Med. Econ. 23(10), 1084–1091 (2020).
40.
Damy T, Elliott P, Gundapaneni B et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Eur. Heart J. 41(Suppl. 2), ehaa946.2142 (2020).
Information & Authors
Information
Published In
Pages: 927 - 938
PubMed: 34142865
Copyright
© 2021 Pfizer Inc. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 18 March 2021
Accepted: 7 May 2021
Published online: 18 June 2021
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0071
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Carol Yen, John W. Epling, Michelle Rockwell, Monifa Vaughn-Cooke, Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors, Diagnostics, 10.3390/diagnostics16020347, 16, 2, (347), (2026).
- Allen Chen, Re-evaluating the access imperative in healthcare in the United States, Journal of Public Health Policy, 10.1057/s41271-025-00612-7, (2026).
- Bruria Hirsh-Raccah, Treatment of Cardiac Amyloidosis—Disease Modifying Therapies in ATTR: Pharmacological Point of View, Cardiac Amyloidosis, 10.1007/978-3-031-88342-2_16, (261-283), (2025).
- Thibaud Damy, Rong Wang, Mathew S. Maurer, Julian D. Gillmore, Marianna Fontana, Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage, European Journal of Heart Failure, 10.1002/ejhf.3696, 27, 12, (2998-3009), (2025).
- Laura De Michieli, Alessandro Lupi, Giulio Sinigiani, Angela Tietto, Alessandro Salvalaggio, Antonio Branca, Stefano Da Pozzo, Stefania Rizzo, Diego Cecchin, Martina Perazzolo Marra, Tamara Berno, Domenico Corrado, Chiara Briani, Alberto Cipriani, Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going, Journal of Clinical Medicine, 10.3390/jcm14103481, 14, 10, (3481), (2025).
- Allen M. Chen, Why Access Matters in Value-Based Healthcare: A Systematic Review, Journal for Healthcare Quality, 10.1097/JHQ.0000000000000471, 47, 2, (2025).
- Ahmad Masri, Yong Chen, A. Carmine Colavecchia, Darrin Benjumea, Aaron Crowley, Priti Jhingran, Matthew Kent, Jenifer Wogen, Cindi Pankratova, Jose Maria Jimenez Alvir, Rahul Bhambri, Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real‐World Evaluation of Clinical Characteristics and Outcomes, Journal of the American Heart Association, 10.1161/JAHA.123.033251, 14, 2, (2025).
- Sergi Yun, Giovanni Palladini, Lisa J. Anderson, Eve Cariou, Ronnie Wang, Franca S. Angeli, Ben Ebede, Pablo Garcia-Pavia, International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction, Amyloid, 10.1080/13506129.2024.2398446, 31, 4, (291-301), (2024).
- Sandra Michaela Ihne-Schubert, Maria Leberzammer, Marcel Weidgans, Stefan Frantz, Hermann Einsele, Stefan Knop, Torben Schubert, Tanja Bratan, Stefan Störk, Silke Neuderth, Single German centre experience with patient journey and care-relevant needs in amyloidosis: The German AMY-NEEDS research and care program, PLOS ONE, 10.1371/journal.pone.0297182, 19, 5, (e0297182), (2024).
- Anson T.C. Lau, Robert J. DiDomenico, Kibum Kim, Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States, International Journal of Cardiology, 10.1016/j.ijcard.2023.131598, 398, (131598), (2024).